September, 2018, Eutropics Pharmaceuticals has been selected for a prestigious NIH/NCI SBIR Phase IIB Bridge Award providing 3 million dollars in non‑dilutive matching funds tied to commercial revenues generated from its PraediCare functional precision oncology platform. This award is designed to bridge the critical gap between completion of Phase II SBIR work and large‑scale market adoption, recognizing both the strong clinical and technical foundation established under prior NCI support and the commercial traction of Eutropics’ ex vivo cancer diagnostics. The 3 million dollars in revenue‑matched funding will support late‑stage clinical validation and commercialization activities, accelerating PraediCare’s deployment as a predictive diagnostic to guide therapy selection and improve outcomes for cancer patients.
